Market closedNon-fractional
Entrada Therapeutics/TRDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Entrada Therapeutics
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Ticker
TRDA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
160
Website
www.entradatx.com
TRDA Metrics
BasicAdvanced
$498M
Market cap
20.14
P/E ratio
$0.70
EPS
-0.39
Beta
-
Dividend rate
Price and volume
Market cap
$498M
Beta
-0.39
Financial strength
Current ratio
2.381
Quick ratio
2.334
Long term debt to equity
21.581
Total debt to equity
24.662
Management effectiveness
Return on assets (TTM)
3.01%
Return on equity (TTM)
9.41%
Valuation
Price to earnings (TTM)
20.139
Price to revenue (TTM)
2.904
Price to book
1.67
Price to tangible book (TTM)
1.67
Price to free cash flow (TTM)
-5.037
Growth
Revenue change (TTM)
544.79%
Earnings per share change (TTM)
-127.90%
3-year earnings per share growth
-69.76%
What the Analysts think about TRDA
Analyst Ratings
Majority rating from 4 analysts.
TRDA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$59M
41.39%
Net income
$23M
-346.32%
Profit margin
39.59%
-274.25%
TRDA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.78
$1.02
-$0.29
$0.68
-
Expected
-$0.69
-$0.74
-$0.17
-$0.59
$0.14
Surprise
13.04%
-238.63%
72.62%
-214.48%
-
TRDA News
AllArticlesVideos
Entrada Therapeutics Announces $100 Million Registered Direct Offering
GlobeNewsWire·2 weeks ago
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
GlobeNewsWire·2 weeks ago
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Entrada Therapeutics stock?
Entrada Therapeutics (TRDA) has a market cap of $498M as of July 05, 2024.
What is the P/E ratio for Entrada Therapeutics stock?
The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 20.14 as of July 05, 2024.
Does Entrada Therapeutics stock pay dividends?
No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Entrada Therapeutics dividend payment date?
Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Entrada Therapeutics?
Entrada Therapeutics (TRDA) has a beta rating of -0.39. This means that it has an inverse relation to market volatility.
Buy or sell Entrada Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.